MECE: a method for enhancing the catalytic efficiency of glycoside hydrolase based on deep neural networks and molecular evolution.


Journal

Science bulletin
ISSN: 2095-9281
Titre abrégé: Sci Bull (Beijing)
Pays: Netherlands
ID NLM: 101655530

Informations de publication

Date de publication:
30 11 2023
Historique:
received: 05 05 2023
revised: 14 07 2023
accepted: 25 09 2023
medline: 5 12 2023
pubmed: 23 10 2023
entrez: 22 10 2023
Statut: ppublish

Résumé

The demand for high efficiency glycoside hydrolases (GHs) is on the rise due to their various industrial applications. However, improving the catalytic efficiency of an enzyme remains a challenge. This investigation showcases the capability of a deep neural network and method for enhancing the catalytic efficiency (MECE) platform to predict mutations that improve catalytic activity in GHs. The MECE platform includes DeepGH, a deep learning model that is able to identify GH families and functional residues. This model was developed utilizing 119 GH family protein sequences obtained from the Carbohydrate-Active enZYmes (CAZy) database. After undergoing ten-fold cross-validation, the DeepGH models exhibited a predictive accuracy of 96.73%. The utilization of gradient-weighted class activation mapping (Grad-CAM) was used to aid us in comprehending the classification features, which in turn facilitated the creation of enzyme mutants. As a result, the MECE platform was validated with the development of CHIS1754-MUT7, a mutant that boasts seven amino acid substitutions. The k

Identifiants

pubmed: 37867059
pii: S2095-9273(23)00674-6
doi: 10.1016/j.scib.2023.09.039
pii:
doi:

Substances chimiques

Glycoside Hydrolases EC 3.2.1.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2793-2805

Subventions

Organisme : National Key R&D Program of China
ID : 2022YFC2105501
Organisme : National Natural Science Foundation of China
ID : 32202720
Organisme : Agricultural Science and Technology Innovation Program
ID : CAAS-ZDRW202304 AND CAAS-ASTIP-G2022-IFST-07
Organisme : Central Public-interest Scientific Institution Basal Research Fund
ID : 1610392020001

Informations de copyright

Copyright © 2023 Science China Press. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest The authors declare that they have no conflict of interest.

Auteurs

Hanqing Liu (H)

Institute of Animal Science, Chinese Academy of Agricultural Sciences, Beijing 100193, China; Biotechnology Research Institute, Chinese Academy of Agricultural Sciences, Beijing 100081, China.

Feifei Guan (F)

Biotechnology Research Institute, Chinese Academy of Agricultural Sciences, Beijing 100081, China. Electronic address: guanfeifei@caas.cn.

Tuoyu Liu (T)

Biotechnology Research Institute, Chinese Academy of Agricultural Sciences, Beijing 100081, China.

Lixin Yang (L)

Biotechnology Research Institute, Chinese Academy of Agricultural Sciences, Beijing 100081, China.

Lingxi Fan (L)

Biotechnology Research Institute, Chinese Academy of Agricultural Sciences, Beijing 100081, China.

Xiaoqing Liu (X)

Biotechnology Research Institute, Chinese Academy of Agricultural Sciences, Beijing 100081, China.

Huiying Luo (H)

Institute of Animal Science, Chinese Academy of Agricultural Sciences, Beijing 100193, China.

Ningfeng Wu (N)

Biotechnology Research Institute, Chinese Academy of Agricultural Sciences, Beijing 100081, China.

Bin Yao (B)

Institute of Animal Science, Chinese Academy of Agricultural Sciences, Beijing 100193, China.

Jian Tian (J)

Institute of Animal Science, Chinese Academy of Agricultural Sciences, Beijing 100193, China; Biotechnology Research Institute, Chinese Academy of Agricultural Sciences, Beijing 100081, China. Electronic address: tianjian@caas.cn.

Huoqing Huang (H)

Institute of Animal Science, Chinese Academy of Agricultural Sciences, Beijing 100193, China. Electronic address: huanghuoqing@caas.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH